The online version of this article (doi:10.1186/s13058-017-0827-4) contains supplementary material, which is available to authorized users.
Cancer is a mosaic of tumor cell subpopulations, where only a minority is responsible for disease recurrence and cancer invasiveness. We focused on one of the most aggressive circulating tumor cells (CTCs) which, from the primitive tumor, spreads to the central nervous system (CNS), evaluating the expression of prognostic and putative cancer stem cell markers in breast cancer (BC) leptomeningeal metastasis (LM).
Flow cytometry immunophenotypic analysis of cerebrospinal fluid (CSF) samples (4.5 ml) was performed in 13 consecutive cases of BCLM. Syndecan-1 (CD138), MUC-1 (CD227) CD45, CD34, and the putative cancer stem cell markers CD15, CD24, CD44, and CD133 surface expression were evaluated on CSF floating tumor cells. The tumor-associated leukocyte population was also characterized.
Despite a low absolute cell number (8 cell/μl, range 1–86), the flow cytometry characterization was successfully conducted in all the samples. Syndecan-1 and MUC-1 overexpression was documented on BC cells in all the samples analyzed; CD44, CD24, CD15, and CD133 in 77%, 75%, 70%, and 45% of cases, respectively. A strong syndecan-1 and MUC-1 expression was also documented by immunohistochemistry on primary breast cancer tissues, performed in four patients. The CSF tumor population was flanked by T lymphocytes, with a different immunophenotype between the CSF and peripheral blood samples (P ≤ 0.02).
Flow cytometry can be successfully employed for solid tumor LM characterization even in CSF samples with low cell count. This in vivo study documents that CSF floating BC cells overexpress prognostic and putative cancer stem cell biomarkers related to tumor invasiveness, potentially representing a molecular target for circulating tumor cell detection and LM treatment monitoring, as well as a primary target for innovative treatment strategies. The T lymphocyte infiltration, documented in all CSF samples, suggests a possible involvement of the CNS lymphatic system in both lymphoid and cancer cell migration into and out of the meninges, supporting the extension of a new form of cellular immunotherapy to LM. Due to the small number of cases, validation on large cohorts of patients are warranted to confirm these findings and to evaluate the impact and value of these results for diagnosis and management of LM.
Additional file 1: Figure S1. Flow cytometry analysis of cerebospinal fluid (CSF) samples of patients with breast cancer leptomeningeal metastasis. Representative dot plot and histogram for CSF breast cancer cells and tumor-associated leukocytes. (PPTX 2013 kb)13058_2017_827_MOESM1_ESM.pptx
Additional file 2: Table S1. Flow cytometry characterization of cerebrospinal fluid (CSF) and peripheral blood (PB) lymphocytes in patients with breast cancer leptomeningeal metastasis. (XLSX 11 kb)13058_2017_827_MOESM2_ESM.xlsx
Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;2(4):S265–88.
Yu Y, Ramena G, Elble RC. The role of cancer stem cells in relapse of solid tumors. Front Biosci. 2012;1:1528–41. CrossRef
Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. Front Biosci. 2012;4:2142–9. CrossRef
Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;15(68):1674–9. CrossRef
Zhenyu P, Guozi Y, Yongxiang W, et al. Thinprep plus Papanicolaou stain method is more sensitive than cytospin-coupled Wright Giems stain method in cerebrospinal fluid cytology for diagnosis of leptomeningeal metastasis from solid tumors. PLoS One. 2015;10(4):e0122016. CrossRef
Moreau P. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol. 2012;49(Suppl):33–46. CrossRef
Hammerich KH, Ayala GE, Wheeler TM. Application of immunohistochemistry to the genitourinary system (prostate, orinary bladder, testis, and kidney). Arch Pathol Lab Med. 2008;132(3):432–40. PubMed
Kadota A, Masutani M, Takei M, Horie T. Evaluation of expression of CD15 and sCD15 in non-small cell lung. Int J Oncol. 1999;15(6):1081–90. PubMed
Nakamori S, Kameyama M, Imaoka S, et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993;53(15):3632–7. PubMed
de Souza VB, Schenka AA. Cancer stem and progenitor-like cells as pharmacological targets in breast cancer treatment. Breast Cancer Basic Clin Res. 2015;9 Suppl 2:45–55.
Sung Jeep K, Yong Seok K, Eun Duok J, et al. Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer. J Breast Cancer. 2015;18(4):347–55. CrossRef
Xinquan LV, Yingzi W, Yimin S, et al. Association between ALDH1+/CD133+ stem-like cells and tumor angiogenesis in invasive ductal breast carcinoma. Oncol Lett. 2016;11(3):1750–6.
Maltoni R, Fici P, Amadori D, et al. Circulating tumor cells in early breast cancer: A connection with vascular invasion. Cancer Lett. 2015;10(367):43–8. CrossRef
Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for leptomeningeal metastasis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 2009;36(suppl):35–45. CrossRef
Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:493–503. CrossRef
Zhou W, Bao S. Reciprocal supportive interplay between glioblastoma and tumor-associated macrophages. Cancers (Basel). 2014;6(2):723–40. CrossRef
- Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study
Carmine Maria Carapella
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II